Nucynta
Product Images NDC 69865-240

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nucynta (NDC 69865-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Depo Nf Sub, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nucynta 01

Chemical structure of the active ingredient in Nucynta ER, showing the molecular arrangement with labeled stereochemistry and hydrochloride salt. The structure includes a benzene ring with a hydroxyl group and side chains including nitrogen atoms.*

FDA Label Image

Nucynta 02

A line graph comparing the percent of patients improved in pain from baseline at week 15 between Nucynta ER and placebo. The x-axis depicts percent improvement in pain, and the y-axis shows the percent of patients improved. Nucynta ER is represented by a dashed black line, and placebo by a solid gray line, illustrating higher patient improvement with Nucynta ER across the range.*

FDA Label Image

Nucynta 03

Line graph depicting percent of patients improved versus percent improvement in pain from baseline at week 12 of the double-blind period. Two lines compare placebo and Nucynta ER, with Nucynta ER showing higher patient improvement percentages across pain improvement levels.*

FDA Label Image

Nucynta 04

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline at week 12 of the double-blind period for Nucynta ER and placebo. Two lines represent the placebo and Nucynta ER groups, showing patient improvement across a range of pain reduction percentages.*

FDA Label Image

Nucynta 05

Nucynta ER 50 mg extended release tablets packaging label showing the tapentadol active ingredient. The label indicates a quantity of 60 tablets and includes usage instructions such as swallowing whole without chewing or crushing. Labeler is Depo NF Sub, LLC.*

FDA Label Image

Nucynta 06

Nucynta ER 100 mg extended release tablets packaging label showing 60 tablets per bottle. The label indicates the active ingredient tapentadol, with instruction to swallow tablets whole. The label includes usage cautions, prescribing information guidance, and storage conditions. The product is labeled by Depo NF Sub, LLC with NDC 69865-245-02.*

FDA Label Image

Nucynta 07

Nucynta ER 150 mg extended release tablets packaging label showing 60 tablets per container. The label includes the active ingredient tapentadol and emphasizes swallowing tablets whole without chewing, crushing, or dissolving. The product is for prescription use only and is labeled by Depo NF Sub, LLC.*

FDA Label Image

Nucynta 08

Nucynta ER 200 mg extended release tablets packaging label showing 60 tablets per container. The label includes the active ingredient tapentadol, directions to swallow tablets whole, and legal cautions about drug transfer. The product is labeled by Depo NF Sub, LLC.*

FDA Label Image

Nucynta 09

Nucynta ER 250 mg extended release tablets label showing tapentadol as the active ingredient. The label indicates a package of 60 tablets, with instructions to swallow whole, not to chew, crush, or dissolve. It includes warnings about federal law transfer restrictions and storage conditions. Labeler is Depo NF Sub, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.